Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313385680> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313385680 endingPage "212.9" @default.
- W4313385680 startingPage "212.9" @default.
- W4313385680 abstract "Abstract Glioblastoma multiforme (GBM) is a lethal cancer of the central nervous system with a median survival rate of 15 months with treatment. Thus, there is a critical need to develop novel therapies for GBM. Immunotherapy is emerging as a promising therapeutic strategy. However, current standard-of-care therapies for GBM, in particular anti-angiogenic therapies that block vascular endothelial growth factor (VEGF), may have undefined consequences on the efficacy of immunotherapy. While this treatment is primarily prescribed to reduce tumor vascularization, multiple immune cell types also express VEGF receptors, including the most potent antigen‑presenting cell, the dendritic cell (DC). Therefore, we assessed the role of anti-VEGF therapy in combination with a novel tumor antigen-specific picornaviral vaccination in the GL261 syngeneic murine model of glioma. We hypothesized that treatment of GL261 glioma-bearing mice with anti‑VEGF therapy will act synergistically with anti-tumor picornaviral vaccination by enhancing DC maturation. We found that VEGF blockade results in a more mature DC phenotype in the brain and tumor-draining lymph node, as demonstrated by an increase in the expression of the co‑stimulatory molecules B7-1 and B7-2. Furthermore, we observed an increase in brain infiltrating, tumor antigen-specific CD8 T cells. This change in immune response directly correlates with a significant reduction in tumor burden, as measured by bioluminescence imaging, and a significantly improved survival rate of mice receiving both anti-VEGF therapy and viral vaccination compared to either treatment alone. Thus, anti-angiogenic therapy can be used in conjunction with and enhance immunotherapy for GBM." @default.
- W4313385680 created "2023-01-06" @default.
- W4313385680 creator A5033341657 @default.
- W4313385680 creator A5044624530 @default.
- W4313385680 creator A5045169479 @default.
- W4313385680 creator A5060051492 @default.
- W4313385680 creator A5065621034 @default.
- W4313385680 creator A5076599272 @default.
- W4313385680 date "2016-05-01" @default.
- W4313385680 modified "2023-09-25" @default.
- W4313385680 title "Immunomodulation mediated by anti-angiogenic therapy improves viral vaccination against GL261 glioma tumors." @default.
- W4313385680 doi "https://doi.org/10.4049/jimmunol.196.supp.212.9" @default.
- W4313385680 hasPublicationYear "2016" @default.
- W4313385680 type Work @default.
- W4313385680 citedByCount "0" @default.
- W4313385680 crossrefType "journal-article" @default.
- W4313385680 hasAuthorship W4313385680A5033341657 @default.
- W4313385680 hasAuthorship W4313385680A5044624530 @default.
- W4313385680 hasAuthorship W4313385680A5045169479 @default.
- W4313385680 hasAuthorship W4313385680A5060051492 @default.
- W4313385680 hasAuthorship W4313385680A5065621034 @default.
- W4313385680 hasAuthorship W4313385680A5076599272 @default.
- W4313385680 hasConcept C111335760 @default.
- W4313385680 hasConcept C142724271 @default.
- W4313385680 hasConcept C147483822 @default.
- W4313385680 hasConcept C161997846 @default.
- W4313385680 hasConcept C167672396 @default.
- W4313385680 hasConcept C203014093 @default.
- W4313385680 hasConcept C22070199 @default.
- W4313385680 hasConcept C2776624504 @default.
- W4313385680 hasConcept C2777701055 @default.
- W4313385680 hasConcept C2778227246 @default.
- W4313385680 hasConcept C2779130545 @default.
- W4313385680 hasConcept C2780849966 @default.
- W4313385680 hasConcept C502942594 @default.
- W4313385680 hasConcept C54009773 @default.
- W4313385680 hasConcept C54355233 @default.
- W4313385680 hasConcept C71924100 @default.
- W4313385680 hasConcept C81885089 @default.
- W4313385680 hasConcept C86803240 @default.
- W4313385680 hasConcept C8891405 @default.
- W4313385680 hasConceptScore W4313385680C111335760 @default.
- W4313385680 hasConceptScore W4313385680C142724271 @default.
- W4313385680 hasConceptScore W4313385680C147483822 @default.
- W4313385680 hasConceptScore W4313385680C161997846 @default.
- W4313385680 hasConceptScore W4313385680C167672396 @default.
- W4313385680 hasConceptScore W4313385680C203014093 @default.
- W4313385680 hasConceptScore W4313385680C22070199 @default.
- W4313385680 hasConceptScore W4313385680C2776624504 @default.
- W4313385680 hasConceptScore W4313385680C2777701055 @default.
- W4313385680 hasConceptScore W4313385680C2778227246 @default.
- W4313385680 hasConceptScore W4313385680C2779130545 @default.
- W4313385680 hasConceptScore W4313385680C2780849966 @default.
- W4313385680 hasConceptScore W4313385680C502942594 @default.
- W4313385680 hasConceptScore W4313385680C54009773 @default.
- W4313385680 hasConceptScore W4313385680C54355233 @default.
- W4313385680 hasConceptScore W4313385680C71924100 @default.
- W4313385680 hasConceptScore W4313385680C81885089 @default.
- W4313385680 hasConceptScore W4313385680C86803240 @default.
- W4313385680 hasConceptScore W4313385680C8891405 @default.
- W4313385680 hasIssue "1_Supplement" @default.
- W4313385680 hasLocation W43133856801 @default.
- W4313385680 hasOpenAccess W4313385680 @default.
- W4313385680 hasPrimaryLocation W43133856801 @default.
- W4313385680 hasRelatedWork W2001055320 @default.
- W4313385680 hasRelatedWork W2019574320 @default.
- W4313385680 hasRelatedWork W2020590412 @default.
- W4313385680 hasRelatedWork W2087634573 @default.
- W4313385680 hasRelatedWork W2220102944 @default.
- W4313385680 hasRelatedWork W2387430262 @default.
- W4313385680 hasRelatedWork W4221063257 @default.
- W4313385680 hasRelatedWork W4285804056 @default.
- W4313385680 hasRelatedWork W4313385680 @default.
- W4313385680 hasRelatedWork W4361282374 @default.
- W4313385680 hasVolume "196" @default.
- W4313385680 isParatext "false" @default.
- W4313385680 isRetracted "false" @default.
- W4313385680 workType "article" @default.